Ellen Chiniara Sells 3,129 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Ellen Chiniara sold 3,129 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $41.75, for a total transaction of $130,635.75. Following the sale, the insider now directly owns 54,826 shares of the company’s stock, valued at $2,288,985.50. This represents a 5.40 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Kymera Therapeutics Stock Down 4.1 %

Shares of KYMR stock traded down $1.69 on Monday, hitting $39.90. The company had a trading volume of 676,526 shares, compared to its average volume of 454,809. The firm has a market cap of $2.58 billion, a P/E ratio of -17.05 and a beta of 2.19. Kymera Therapeutics, Inc. has a twelve month low of $25.02 and a twelve month high of $53.27. The company has a 50-day moving average price of $44.67 and a 200-day moving average price of $43.82.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.01. The business had revenue of $3.74 million for the quarter, compared to analyst estimates of $10.34 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business’s quarterly revenue was down 20.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.90) EPS. Equities research analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on KYMR shares. Truist Financial reiterated a “buy” rating and set a $53.00 target price (down from $54.00) on shares of Kymera Therapeutics in a report on Friday, November 1st. Guggenheim lifted their target price on Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Wells Fargo & Company upgraded shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $38.00 to $57.00 in a report on Monday, December 2nd. Leerink Partners reiterated an “outperform” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research note on Friday, December 27th. Finally, Morgan Stanley raised their target price on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 6th. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Kymera Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $55.38.

Institutional Trading of Kymera Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jennison Associates LLC raised its position in shares of Kymera Therapeutics by 85.8% in the third quarter. Jennison Associates LLC now owns 797,681 shares of the company’s stock worth $37,754,000 after acquiring an additional 368,394 shares during the period. Wellington Management Group LLP lifted its position in shares of Kymera Therapeutics by 7.2% during the 3rd quarter. Wellington Management Group LLP now owns 4,618,359 shares of the company’s stock valued at $218,587,000 after buying an additional 308,954 shares in the last quarter. FMR LLC grew its stake in Kymera Therapeutics by 5.8% in the 3rd quarter. FMR LLC now owns 5,109,141 shares of the company’s stock valued at $241,816,000 after acquiring an additional 282,301 shares during the period. Driehaus Capital Management LLC acquired a new stake in Kymera Therapeutics in the 2nd quarter valued at $6,669,000. Finally, Renaissance Technologies LLC purchased a new stake in Kymera Therapeutics in the 2nd quarter worth $4,271,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.